VENUSREM — Venus Remedies Income Statement
0.000.00%
Last trade - 00:00
- IN₹4.39bn
- IN₹4.08bn
- IN₹5.56bn
- 48
- 56
- 92
- 78
2019 March 31st | C2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,219 | 3,393 | 5,481 | 5,986 | 5,555 |
Cost of Revenue | |||||
Gross Profit | 1,399 | 1,650 | 2,073 | 2,132 | 2,123 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,323 | 3,393 | 5,062 | 5,696 | 5,271 |
Operating Profit | -104 | -0.058 | 419 | 290 | 284 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -297 | -80.4 | 486 | 364 | 379 |
Provision for Income Taxes | |||||
Net Income After Taxes | -286 | -100 | 618 | 407 | 266 |
Net Income Before Extraordinary Items | |||||
Net Income | -286 | -100 | 618 | 407 | 266 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -286 | -100 | 618 | 407 | 266 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -18.4 | -3.46 | 37.7 | 30.9 | 19.9 |
Dividends per Share |